Calidi Biotherapeutics (NYSE:CLDI – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.03, Yahoo Finance reports.
Calidi Biotherapeutics Stock Performance
Shares of NYSE CLDI remained flat at $1.65 during trading hours on Wednesday. The stock had a trading volume of 11,760 shares, compared to its average volume of 155,274. Calidi Biotherapeutics has a one year low of $1.41 and a one year high of $137.90.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on CLDI shares. LADENBURG THALM/SH SH started coverage on Calidi Biotherapeutics in a research note on Thursday, June 27th. They issued a “buy” rating and a $10.00 target price for the company. Robert W. Baird dropped their target price on Calidi Biotherapeutics from $45.00 to $20.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th.
About Calidi Biotherapeutics
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc, formerly known as First Light Acquisition Group, is based in SAN DIEGO.
Further Reading
- Five stocks we like better than Calidi Biotherapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Microsoft Stock: Is Now The Time To Be Greedy?
- Insider Trades May Not Tell You What You Think
- How to Invest in Mutual Funds
- Which Wall Street Analysts are the Most Accurate?
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
